2,3,4-Trihydroxybenzophenone Disassembles Amyloid β Aggregates and Ameliorates Synaptic Deficits
Open Access
- 2 March 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 320
Abstract
Background/Objectives: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder for which no disease-modifying therapy that halts or substantially slows disease progression is currently available. Although antibody therapies targeting amyloid β (Aβ) have recently received FDA approval, their high cost, limited efficacy, and potential adverse effects highlight the need for alternative solutions. Therefore, the development of low-molecular-weight compounds capable of reducing toxic Aβ aggregates is of considerable interest. In this study, we investigated the effects of 2,3,4-trihydroxybenzophenone (THB) on the inhibition and disassembly of Aβ1–42 aggregates through in vitro and in vivo experiments. Methods: In vitro assays were performed to evaluate the effects of THB on Aβ1–42 aggregation and fibril disassembly. Cell viability assays and hippocampal slice electrophysiology were conducted to assess neurotoxicity and synaptic function. In vivo effects were examined in Aβ1–42 aggregate-injected mice and in 5 Familial AD mutations (5XFAD) mice using behavioral, histological, and electrophysiological analyses. Results: THB inhibited Aβ1–42 aggregation in a concentration-dependent manner and promoted the disassembly of preformed fibrils. THB attenuated Aβ1–42-induced Neuro2a cell death and restored Aβ1–42 aggregate-associated long-term potentiation (LTP) deficits in hippocampal slices. In Aβ1–42 aggregate-injected and 5XFAD mice, THB reduced amyloid pathology and neuroinflammatory markers and improved synaptic function and memory performance. Conclusions: These findings suggest that THB modulates pathogenic Aβ1–42 assemblies and provides a structural basis for the development of small-molecule modulators of Aβ1–42 aggregation with potential preventive or disease-modifying applications in AD.Keywords
Funding Information
- Konkuk University
This publication has 29 references indexed in Scilit:
- 2,3,4-Trihydroxybenzophenone-induced cardiac and neurological toxicity: Heart-brain interaction mediated by regulation of pgam1a and pgk1 involved in glycolysis and gluconeogenesis in zebrafishScience of The Total Environment, 2025
- Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease managementJournal of Controlled Release, 2024
- Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer DiseaseJAMA Neurology, 2021
- The β-Secretase BACE1 in Alzheimer’s DiseaseBiological Psychiatry, 2021
- Characterization of UV and chlorine contributions to transformation of 2,3,4-trihydroxybenzophenone under combined UV-chlorine treatmentChemosphere, 2021
- Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- BACE1 inhibitors: Current status and future directions in treating Alzheimer's diseaseMedicinal Research Reviews, 2019
- 2,2′,4‐Trihydroxybenzophenone: Crystal Structure, and Anti‐Inflammatory and Antioxidant ActivitiesChemistry & Biodiversity, 2007
- Alzheimer's disease: Aβ, tau and synaptic dysfunctionTrends in Molecular Medicine, 2005
- Estrogenic and antiandrogenic activities of 17 benzophenone derivatives used as UV stabilizers and sunscreensToxicology and Applied Pharmacology, 2005